9. Information in relation to the person subject to the notification obligation 2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are ...

1. Issuer Details ISIN GB00BYT1DJ19 Issuer Name INTERMEDIATE CAPITAL GROUP PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of voting rights 3. Details of person ...

Australia, which was considered the weakest in Group B like Korea in the Premier 12, took its first victory.Australia defeated the Dominican Republic 5-0 in ...

Merck KGaA and Abbisko Therapeutics have announced positive results from a late-stage study of pimicotinib in patients with ...

Abbisko announces positive results from phase 3 MANEUVER study of pimicotinib to treat tenosynovial giant cell tumour: Shanghai Wednesday, November 13, 2024, 18:00 Hrs [IST] Abbis ...

Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) ...

Abbisko’s small molecule drug pimicotinib has smashed the primary goal of a phase 3 trial for the treatment of tenosynovial ...

The MANEUVER study met the primary endpoint with an objective response rate (ORR) at week 25 of 54.0% compared with 3.2% for placebo (p- Statistically significant ...

These Phase III data from MANEUVER confirm results of Abbisko’s Phase I study, indicating that targeting CSF-1R with pimicotinib ... Macau, and Taiwan, with an option for the rest of world ...

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that the Phase III MANEUVER trial ...

Merck KGaA, Darmstadt, Germany holds commercial license for pimicotinib in Chinese mainland, Hong Kong, Macau, and Taiwan ... s selective inhibition of CSF-1R, this investigational medicine ...

and Taiwan, with an option for the rest of world including the US. The pivotal Phase III MANEUVER study is a three-part, randomized, double-blind, placebo-controlled study to assess the efficacy and ...